strides

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

Paribus on the Rise

The past few weeks have seen a whirlwind of activity for the team, bridging over to Cardano and raising awareness of Paribus. The upcoming weeks and months will be equally exciting as we are poised to deliver more elements from our roadmap. As more of the circulating PBX supply transitions to Cardano, we’ve been making strides toward getting the token listed on two more decentralized exchanges (DEXs). We’ll be able to announce each one as they launch, so stay tuned to our Discord, Twitter, and Telegram channels for the latest

Crypto Oasis Members Newsletter

Welcome to the Crypto Oasis Members Newsletter These past weeks have been filled with exciting events and initiatives at the Crypto Oasis and we want to take this opportunity to share some of the highlights with you. Our ecosystem and partners have been up to stimulating initiatives! Latest Updates on Member Additions We are thrilled to share that true to our precept of being the fastest-growing blockchain ecosystem in the world, our community keeps growing at a fast rate! We have recently witnessed a significant increase in Crypto Oasis memberships,